BiotechTube
Home/EmeraMed/Kathryn Wachsman
KW

Kathryn Wachsman

Board Secretary

EmeraMed

Therapeutic Areas

Heavy Metal ToxicityCOPDInfectious Disease

EmeraMed Pipeline

DrugIndicationPhase
Emeramide for Mercury ToxicityMercury PoisoningPhase 2
Emeramide for COPDChronic Obstructive Pulmonary DiseasePhase 2
Emeramide for COVID-19COVID-19Preclinical

Leadership Team at EmeraMed

BH
Boyd Haley, PhD
Chief Scientist & CEO
RK
Ragnar Klingberg
Board Member
PR
Paul Reicherter, MD
Board Member
View full EmeraMed profile